On October 22, 2025, Telomir Pharmaceuticals, Inc. announced new data showing that their compound Telomir-1 is effective in reducing DNA methylation in key cancer-related genes, outperforming conventional chemotherapy and Rapamycin in an aggressive prostate cancer model. This suggests potential benefits of Telomir-1 for cancer treatment, highlighting its unique epigenetic activity.